颜红兵

• 1:中国医学科学院阜外医院深圳医院
• 2:国家心血管病中心北京协和医学院中国医学科学院阜外医院冠心病诊治中心

摘要(Abstract)：

2023年欧洲心脏病学会急性冠状动脉综合征（ACS）管理指南涵盖了不稳定型心绞痛和所有类型急性心肌梗死的全面管理，重新诠释了有创治疗策略（合并多支冠状动脉病变、心搏骤停和心原性休克），提出了详细的抗栓治疗（抗凝和抗血小板）建议，阐述了长期管理以减少重复事件发生风险的重要性，增加了癌症患者合并ACS处理的新章节，值得临床工作者学习。

关键词(KeyWords)： 急性冠状动脉综合征;欧洲心脏病学会;指南解读

Abstract:

Keywords:

基金项目(Foundation): 深圳市医学重点学科（2020-2024年）（心血管内科）深圳市医疗卫生“三名工程”中国医学科学院阜外医院颜红兵教授急性冠状动脉综合征诊治团队

作者(Author): 颜红兵

参考文献(References)：

• [1]Byrne RA,Rossello X,Coughlan JJ,et al.2023 ESC Guidelines for the management of acute coronary syndromes[J].Eur Heart J,2023,44(38):3720-3826.DOI:10.1093/eurheartj/ehad191.
• [2]Ibanez B,James S,Agewall S,et al.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC)[J].Eur Heart J,2018,39(2):119-177.DOI:10.1093/eurheartj/ehx393.
• [3] Collet JP,Thiele H,Barbato E,et al.2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J].Eur Heart J,2021,42(14):1289-1367.DOI:10.1093/eurheartj/ehaa575.
• [4]Kite TA,Kurmani SA,Bountziouka V,et al.Timing of invasive strategy in non-ST-elevation acute coronary syndrome:a meta-analysis of randomized controlled trials[J].Eur Heart J,2022,43(33):3148-3161.DOI:10.1093/eurheartj/ehac213.
• [5] Mehta SR,Wood DA,Storey RF,et al.Complete revascularization with multivessel PCI for myocardial infarction[J].N Engl J Med,2019,381(15):1411-1421.DOI:10.1056/NEJMoa1907775.
• [6] Bainey KR,Engstrum T,Smits PC,et al.Complete vs culprit-lesion-only revascularization for ST-segment elevation myocardial infarction:a systematic review and Meta-analysis[J].JAMA Cardiol,2020,5(8):881-888.DOI:10.1001/jamacardio.2020.1251.
• [7]Denormandie P,Simon T,Cayla G,et al.Compared outcomes of ST-segment-elevation myocardial infarction patients with multivessel disease treated with primary percutaneous coronary intervention and preserved fractional flow reserve of nonculprit lesions treated conservatively and of those with low fractional flow reserve managed invasively:insights from the FLOWER-MI trial[J].Circ Cardiovasc Interv,2021,14(11):e011314.DOI:10.1161/CIRCINTERVENTIONS.121.0113142.
• [8]Rathod KS,Koganti S,Jain AK,et al.Complete versus culprit-only lesion intervention in patients with acute coronary syndromes[J].J Am Coll Cardiol,2018,72(17):1989-1999.DOI:10.1016/j.jacc.2018.07.089.
• [9]Desch S,Freund A,Akin I,et al.Angiography after outof-hospital cardiac arrest without ST-segment elevation[J].N Engl J Med,2021,385(27):2544-2553.DOI:10.1056/NEJMoa2101909.
• [10] Lemkes JS,Janssens GN,van der Hoeven NW,et al.Coronary angiography after cardiac arrest without ST-Segmentelevation[J].N Engl J Med,2019,380(15):1397-1407.DOI:10.1056/NEJMoa1816897.
• [11] Heyne S,Macherey S,Meertens MM,et al.Coronary angiography after cardiac arrest without ST-elevati on myocardial infarction:a network Meta-analysis[J].Eur Heart J,2023,44(12):1040-1054.DOI:10.1093/eurheartj/ehac611.
• [12]Dankiewicz J,Cronberg T,Lilja G,et al.Hypothermia versus normothermia after out-of-hospital cardiac arrest[J].N Engl J Med,2021,384(24):2283-2294.DOI:10.1056/NEJMoa2100591.
• [13]Thiele H,Akin I,Sandri M,et al.PCI strategies in patients with acute myocardial infarction and cardiogenic shock[J].N Engl J Med,2017,377(25):2419-2432.DOI:10.1056/NEJMoa1710261.
• [14]Thiele H,Zeymer U,Akin I,et al.Extracorporeal life support in infarct-related cardiogenic shock[J].N Engl J Med,2023,389(14):1286-1297.DOI:10.1056/NEJMoa2307227.
• [15]Li Y,Liang Z,Qin L,et al.Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention:a randomied trial[J].Lancet,2022,400(10366):1847-1857.DOI:10.1016/S0140-6736(22)01999-7.
• [16]Mehran R,Baber U,Sharma SK,et al.Ticagrelor with or without aspirin in high-risk patients after PCI[J].N Engl J Med,2019,381(21):2032-2042.DOI:10.1056/NEJMoa1908419.
• [17]Hahn J,Song YB,Oh JH,et al.Effect of P2Y_(12)inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention:the SMART-CHOICE randomized clinical trial[J].JAMA,2019,321(24):2428-2437.DOI:10.1001/jama.2019.8146.
• [18]Vranckx P,Valgimigli M,Jüni P,et al.Ticagrelor plus aspirin for 1 month,followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months,followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent:a multicenter,open-label,randomized superiority trial[J].Lancet,2018,392(10151):940-949.DOI:10.1016/S0140-6736(18)31858-0.
• [19]Watanabe H,Morimoto T,Natsuaki M,et al.Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome:the STOPDAPT-2 ACS randomized clinical Trial[J].JAMA Cardiol,2022,7(4):407-417.DOI:10.1001/j amacardio.2021.5244.
• [20]Valgimigli M,Frigoli E,Heg D,et al.Dual antiplatelet therapy after PCI in patients at high bleeding risk[J].New Engl J Med,2021,385(18):1643-1655.DOI:10.1056/NEJMoa2108749.
• [21]曾和松,颜红兵,余小平.基因分型导向抗血小板治疗的曙光——深度解析TAILOR PCI研究[J].中国介入心脏病学杂志,2020,28(4):224-227.DOI:10.3969/j.issn.1004-8812.2020.04.009.
• [22]颜红兵,余小平,霍勇.迈向病理生物学导向下抗血小板治疗——解读美国心脏病学会2021年冠心病抗血小板治疗临床研究[J].中国介入心脏病学杂志,2021,29(7):411-415.DOI:10.3969/j.issn.1004-8812.2021.07.009.